Overview
BPC-157 (Body Protection Compound) is a synthetic 15-amino-acid peptide derived from a protein found in human gastric juice. It is the most popular regenerative peptide in the biohacking community, with a large body of animal research on tendon, ligament, muscle and gut healing.
The critical caveat: virtually all published research is preclinical. Human trials are essentially nonexistent, so everything known about dosing and effects in people comes from anecdotal use.
How It Works
BPC-157 appears to promote angiogenesis — the formation of new blood vessels — which is the rate-limiting step in healing poorly vascularized tissues like tendons. It also modulates growth factor expression (including VEGF and EGF), influences the nitric oxide system, and protects the gastrointestinal mucosa.
Systemic vs local
Animal studies show healing effects even when the peptide is administered far from the injury site, suggesting systemic action. Users nonetheless commonly inject near the injury, a practice based on intuition rather than evidence.
Key Benefits
Tendon and ligament repair — the strongest animal evidence; accelerated healing of transected Achilles tendons in rats is the landmark finding.
Gut health — protective and healing effects in models of ulcer, IBD and leaky gut; oral use targets this.
Muscle and bone — faster recovery in crush injury and fracture models.
Neuroprotection — preliminary evidence in traumatic brain injury and nerve damage models.
Side Effects & Considerations
No human safety data exists. Animal studies show remarkably low toxicity, but absence of evidence is not evidence of absence — long-term effects, including any theoretical cancer risk from pro-angiogenic activity, are unknown.
Practical warnings
BPC-157 is not approved for human use anywhere and is prohibited by WADA. The grey market is unregulated: independent testing of research peptides routinely finds underdosed or contaminated vials. Anyone using it should understand they are conducting an experiment on themselves with an n of 1.
Dosage protocols
| Protocol | Dosage | Frequency | Duration | Notes |
|---|---|---|---|---|
| Common anecdotal | 250-500 mcg | 1-2 times daily | 4-6 weeks | Subcutaneous injection. No human dose-ranging studies exist — these figures are community convention, not science. |
| Oral (gut) | 500 mcg | 1-2 times daily | 4-8 weeks | Stable arginate salt form is used orally for gastrointestinal goals. |
Warnings
No human trials. Not approved for human use. WADA prohibited. Source quality is unverified on the grey market.